Richard Lock1, Hernan Carol1, John M Maris2, E Anders Kolb3, Richard Gorlick4, C Patrick Reynolds5, Min H Kang5, Stephen T Keir6, Jianrong Wu7, Andrei Purmal8, Andrei Gudkov9, Dias Kurmashev10, Raushan T Kurmasheva10, Peter J Houghton10, Malcolm A Smith11. 1. Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia. 2. Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania. 3. A.I. duPont Hospital for Children, Wilmington, Delaware. 4. The Children's Hospital at Montefiore, Bronx, New York. 5. Texas Tech University Health Sciences Center, Lubbock, Texas. 6. Duke University Medical Center, Durham, North Carolina. 7. St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Incuron LLC, Buffalo, New York. 9. Roswell Park Cancer Institute, Buffalo, New York. 10. Nationwide Children's Hospital, Columbus, Ohio. 11. Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland.
Abstract
BACKGROUND: CBL0137 is a novel drug that modulates FAcilitates Chromatin Transcription (FACT), resulting in simultaneous nuclear factor-κB suppression, heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neuroblastoma. PROCEDURES: CBL0137 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro cell line panel at concentrations ranging from 1.0 nM to 10.0 μM and against the PPTP in vivo solid tumor xenograft and acute lymphocytic leukemia (ALL) panels at 50 mg/kg administered intravenously weekly for 4 weeks. RESULTS: The median relative IC50 (rIC50 ) value for the PPTP cell lines was 0.28 μM (range: 0.13-0.80 μM). There were no significant differences in rIC50 values by histotype. CBL0137 induced significant differences in event-free survival (EFS) distribution compared to control in 10 of 31 (32%) evaluable solid tumor xenografts and in eight of eight (100%) evaluable ALL xenografts. Significance differences in EFS distribution were observed in four of six osteosarcoma lines, three of three rhabdoid tumor lines and two of six rhabdomyosarcoma lines. No objective responses were observed among the solid tumor xenografts. For the ALL panel, one xenograft achieved complete response and four achieved partial response. CONCLUSIONS: The most consistent in vivo activity for CBL0137 was observed against ALL xenografts, with some solid tumor xenograft lines showing tumor growth delay. It will be important to relate the drug levels in mice at 50 mg/kg to those in humans at the recommended phase 2 dose.
BACKGROUND:CBL0137 is a novel drug that modulates FAcilitates Chromatin Transcription (FACT), resulting in simultaneous nuclear factor-κB suppression, heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neuroblastoma. PROCEDURES: CBL0137 was tested against the Pediatric Preclinical Testing Program (PPTP) in vitro cell line panel at concentrations ranging from 1.0 nM to 10.0 μM and against the PPTP in vivo solid tumor xenograft and acute lymphocytic leukemia (ALL) panels at 50 mg/kg administered intravenously weekly for 4 weeks. RESULTS: The median relative IC50 (rIC50 ) value for the PPTP cell lines was 0.28 μM (range: 0.13-0.80 μM). There were no significant differences in rIC50 values by histotype. CBL0137 induced significant differences in event-free survival (EFS) distribution compared to control in 10 of 31 (32%) evaluable solid tumor xenografts and in eight of eight (100%) evaluable ALL xenografts. Significance differences in EFS distribution were observed in four of six osteosarcoma lines, three of three rhabdoid tumor lines and two of six rhabdomyosarcoma lines. No objective responses were observed among the solid tumor xenografts. For the ALL panel, one xenograft achieved complete response and four achieved partial response. CONCLUSIONS: The most consistent in vivo activity for CBL0137 was observed against ALL xenografts, with some solid tumor xenograft lines showing tumor growth delay. It will be important to relate the drug levels in mice at 50 mg/kg to those in humans at the recommended phase 2 dose.
Authors: Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds Journal: Pediatr Blood Cancer Date: 2010-10-04 Impact factor: 3.167
Authors: M Wu; H Lee; R E Bellas; S L Schauer; M Arsura; D Katz; M J FitzGerald; T L Rothstein; D H Sherr; G E Sonenshein Journal: EMBO J Date: 1996-09-02 Impact factor: 11.598
Authors: Huating Wang; Ramiro Garzon; Hao Sun; Katherine J Ladner; Ravi Singh; Jason Dahlman; Alfred Cheng; Brett M Hall; Stephen J Qualman; Dawn S Chandler; Carlo M Croce; Denis C Guttridge Journal: Cancer Cell Date: 2008-11-04 Impact factor: 31.743
Authors: Daniel R Carter; Jayne Murray; Belamy B Cheung; Laura Gamble; Jessica Koach; Joanna Tsang; Selina Sutton; Heyam Kalla; Sarah Syed; Andrew J Gifford; Natalia Issaeva; Asel Biktasova; Bernard Atmadibrata; Yuting Sun; Nicolas Sokolowski; Dora Ling; Patrick Y Kim; Hannah Webber; Ashleigh Clark; Michelle Ruhle; Bing Liu; André Oberthuer; Matthias Fischer; Jennifer Byrne; Federica Saletta; Le Myo Thwe; Andrei Purmal; Gary Haderski; Catherine Burkhart; Frank Speleman; Katleen De Preter; Anneleen Beckers; David S Ziegler; Tao Liu; Katerina V Gurova; Andrei V Gudkov; Murray D Norris; Michelle Haber; Glenn M Marshall Journal: Sci Transl Med Date: 2015-11-04 Impact factor: 17.956
Authors: Lin Xiao; Klaartje Somers; Murray D Norris; Michelle Haber; Jayne Murray; Ruby Pandher; Mawar Karsa; Emma Ronca; Angelika Bongers; Rachael Terry; Anahid Ehteda; Laura D Gamble; Natalia Issaeva; Katerina I Leonova; Aisling O'Connor; Chelsea Mayoh; Pooja Venkat; Hazel Quek; Jennifer Brand; Frances K Kusuma; Jessica A Pettitt; Erin Mosmann; Adam Kearns; Georgina Eden; Stephanie Alfred; Sophie Allan; Lei Zhai; Alvin Kamili; Andrew J Gifford; Daniel R Carter; Michelle J Henderson; Jamie I Fletcher; Glenn Marshall; Ricky W Johnstone; Anthony J Cesare; David S Ziegler; Andrei V Gudkov; Katerina V Gurova Journal: Clin Cancer Res Date: 2021-05-16 Impact factor: 12.531
Authors: Minhui Chen; Craig M Brackett; Lyudmila G Burdelya; Achamaporn Punnanitinont; Santosh K Patnaik; Junko Matsuzaki; Adekunle O Odunsi; Andrei V Gudkov; Anurag K Singh; Elizabeth A Repasky; Katerina V Gurova Journal: Cancer Immunol Immunother Date: 2021-01-13 Impact factor: 6.630
Authors: Stella Pearson; Baoqiang Guo; Andrew Pierce; Narges Azadbakht; Julie A Brazzatti; Stefano Patassini; Sonia Mulero-Navarro; Stefan Meyer; Christian Flotho; Bruce D Gelb; Anthony D Whetton Journal: J Proteome Res Date: 2019-11-12 Impact factor: 4.466